Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancers

William M. Grady, Lois L. Myeroff, Sandra E. Swinler, Ashwani Rajput, Sam Thiagalingam, James D. Lutterbaugh, Aaron Neumann, Michael G. Brattain, Jay Chang, Seong Jin Kim, Ken W. Kinzler, Bert Vogelstein, James K.V. Willson, Sanford Markowitz

Research output: Contribution to journalArticle

328 Citations (Scopus)

Abstract

We previously demonstrated that mutational inactivation of transforming growth factor β type II receptors (RIIs) is very common among the 13% of human colon cancers with microsatellite instability. These mutations principally cluster in the BAT-RII polyadenine sequence repeat. Among microsatellite stable (MSS) colon cancers, we now find that non-BAT-RII point mutations inactivate RII in another 15% of cases, thus doubling the known number of colon cancers in which RII mutations are pathogenetic. Functional analysis confirms that these mutations inactivate RII signaling. Moreover, another 55% of MSS colon cancers demonstrate a transforming growth factor β signaling blockade distal to RII. The transforming growth factor β pathway and RII in particular are major targets for inactivation in MSS colon cancers as well as in colon cancers with microsatellite instability.

Original languageEnglish (US)
Pages (from-to)320-324
Number of pages5
JournalCancer Research
Volume59
Issue number2
StatePublished - Jan 16 1999

Fingerprint

Growth Factor Receptors
Transforming Growth Factors
Microsatellite Repeats
Colonic Neoplasms
Microsatellite Instability
Mutation
Point Mutation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Grady, W. M., Myeroff, L. L., Swinler, S. E., Rajput, A., Thiagalingam, S., Lutterbaugh, J. D., ... Markowitz, S. (1999). Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancers. Cancer Research, 59(2), 320-324.

Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancers. / Grady, William M.; Myeroff, Lois L.; Swinler, Sandra E.; Rajput, Ashwani; Thiagalingam, Sam; Lutterbaugh, James D.; Neumann, Aaron; Brattain, Michael G.; Chang, Jay; Kim, Seong Jin; Kinzler, Ken W.; Vogelstein, Bert; Willson, James K.V.; Markowitz, Sanford.

In: Cancer Research, Vol. 59, No. 2, 16.01.1999, p. 320-324.

Research output: Contribution to journalArticle

Grady, WM, Myeroff, LL, Swinler, SE, Rajput, A, Thiagalingam, S, Lutterbaugh, JD, Neumann, A, Brattain, MG, Chang, J, Kim, SJ, Kinzler, KW, Vogelstein, B, Willson, JKV & Markowitz, S 1999, 'Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancers', Cancer Research, vol. 59, no. 2, pp. 320-324.
Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh JD et al. Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancers. Cancer Research. 1999 Jan 16;59(2):320-324.
Grady, William M. ; Myeroff, Lois L. ; Swinler, Sandra E. ; Rajput, Ashwani ; Thiagalingam, Sam ; Lutterbaugh, James D. ; Neumann, Aaron ; Brattain, Michael G. ; Chang, Jay ; Kim, Seong Jin ; Kinzler, Ken W. ; Vogelstein, Bert ; Willson, James K.V. ; Markowitz, Sanford. / Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancers. In: Cancer Research. 1999 ; Vol. 59, No. 2. pp. 320-324.
@article{7bed9c55687746b0a7fb70162c4a6b47,
title = "Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancers",
abstract = "We previously demonstrated that mutational inactivation of transforming growth factor β type II receptors (RIIs) is very common among the 13{\%} of human colon cancers with microsatellite instability. These mutations principally cluster in the BAT-RII polyadenine sequence repeat. Among microsatellite stable (MSS) colon cancers, we now find that non-BAT-RII point mutations inactivate RII in another 15{\%} of cases, thus doubling the known number of colon cancers in which RII mutations are pathogenetic. Functional analysis confirms that these mutations inactivate RII signaling. Moreover, another 55{\%} of MSS colon cancers demonstrate a transforming growth factor β signaling blockade distal to RII. The transforming growth factor β pathway and RII in particular are major targets for inactivation in MSS colon cancers as well as in colon cancers with microsatellite instability.",
author = "Grady, {William M.} and Myeroff, {Lois L.} and Swinler, {Sandra E.} and Ashwani Rajput and Sam Thiagalingam and Lutterbaugh, {James D.} and Aaron Neumann and Brattain, {Michael G.} and Jay Chang and Kim, {Seong Jin} and Kinzler, {Ken W.} and Bert Vogelstein and Willson, {James K.V.} and Sanford Markowitz",
year = "1999",
month = "1",
day = "16",
language = "English (US)",
volume = "59",
pages = "320--324",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancers

AU - Grady, William M.

AU - Myeroff, Lois L.

AU - Swinler, Sandra E.

AU - Rajput, Ashwani

AU - Thiagalingam, Sam

AU - Lutterbaugh, James D.

AU - Neumann, Aaron

AU - Brattain, Michael G.

AU - Chang, Jay

AU - Kim, Seong Jin

AU - Kinzler, Ken W.

AU - Vogelstein, Bert

AU - Willson, James K.V.

AU - Markowitz, Sanford

PY - 1999/1/16

Y1 - 1999/1/16

N2 - We previously demonstrated that mutational inactivation of transforming growth factor β type II receptors (RIIs) is very common among the 13% of human colon cancers with microsatellite instability. These mutations principally cluster in the BAT-RII polyadenine sequence repeat. Among microsatellite stable (MSS) colon cancers, we now find that non-BAT-RII point mutations inactivate RII in another 15% of cases, thus doubling the known number of colon cancers in which RII mutations are pathogenetic. Functional analysis confirms that these mutations inactivate RII signaling. Moreover, another 55% of MSS colon cancers demonstrate a transforming growth factor β signaling blockade distal to RII. The transforming growth factor β pathway and RII in particular are major targets for inactivation in MSS colon cancers as well as in colon cancers with microsatellite instability.

AB - We previously demonstrated that mutational inactivation of transforming growth factor β type II receptors (RIIs) is very common among the 13% of human colon cancers with microsatellite instability. These mutations principally cluster in the BAT-RII polyadenine sequence repeat. Among microsatellite stable (MSS) colon cancers, we now find that non-BAT-RII point mutations inactivate RII in another 15% of cases, thus doubling the known number of colon cancers in which RII mutations are pathogenetic. Functional analysis confirms that these mutations inactivate RII signaling. Moreover, another 55% of MSS colon cancers demonstrate a transforming growth factor β signaling blockade distal to RII. The transforming growth factor β pathway and RII in particular are major targets for inactivation in MSS colon cancers as well as in colon cancers with microsatellite instability.

UR - http://www.scopus.com/inward/record.url?scp=0033555627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033555627&partnerID=8YFLogxK

M3 - Article

C2 - 9927040

AN - SCOPUS:0033555627

VL - 59

SP - 320

EP - 324

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 2

ER -